1. Home
  2. KMDA vs EHAB Comparison

KMDA vs EHAB Comparison

Compare KMDA & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KMDA
  • EHAB
  • Stock Information
  • Founded
  • KMDA 1990
  • EHAB 2014
  • Country
  • KMDA Israel
  • EHAB United States
  • Employees
  • KMDA N/A
  • EHAB N/A
  • Industry
  • KMDA Biotechnology: Pharmaceutical Preparations
  • EHAB Hospital/Nursing Management
  • Sector
  • KMDA Health Care
  • EHAB Health Care
  • Exchange
  • KMDA Nasdaq
  • EHAB Nasdaq
  • Market Cap
  • KMDA 410.6M
  • EHAB 409.1M
  • IPO Year
  • KMDA N/A
  • EHAB N/A
  • Fundamental
  • Price
  • KMDA $7.32
  • EHAB $7.77
  • Analyst Decision
  • KMDA Strong Buy
  • EHAB Buy
  • Analyst Count
  • KMDA 2
  • EHAB 3
  • Target Price
  • KMDA $13.00
  • EHAB $8.67
  • AVG Volume (30 Days)
  • KMDA 51.8K
  • EHAB 438.7K
  • Earning Date
  • KMDA 08-13-2025
  • EHAB 11-05-2025
  • Dividend Yield
  • KMDA 2.80%
  • EHAB N/A
  • EPS Growth
  • KMDA 27.97
  • EHAB N/A
  • EPS
  • KMDA 0.32
  • EHAB N/A
  • Revenue
  • KMDA $169,517,000.00
  • EHAB $1,037,800,000.00
  • Revenue This Year
  • KMDA $14.49
  • EHAB $4.95
  • Revenue Next Year
  • KMDA $10.12
  • EHAB $4.33
  • P/E Ratio
  • KMDA $21.69
  • EHAB N/A
  • Revenue Growth
  • KMDA 9.67
  • EHAB N/A
  • 52 Week Low
  • KMDA $5.17
  • EHAB $6.47
  • 52 Week High
  • KMDA $9.16
  • EHAB $10.91
  • Technical
  • Relative Strength Index (RSI)
  • KMDA 54.83
  • EHAB 51.42
  • Support Level
  • KMDA $6.90
  • EHAB $7.77
  • Resistance Level
  • KMDA $7.43
  • EHAB $8.01
  • Average True Range (ATR)
  • KMDA 0.19
  • EHAB 0.18
  • MACD
  • KMDA 0.03
  • EHAB -0.02
  • Stochastic Oscillator
  • KMDA 80.19
  • EHAB 11.30

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About EHAB Enhabit Inc.

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

Share on Social Networks: